| Old Articles: <Older 3271-3280 Newer> |
|---|
 |
Chemistry World
March 21, 2013
Andy Extance |
Court convicts ex-Aptuit researcher over drug data Steven Eaton, a former employee at drug discovery and development firm Aptuit's Riccarton site in Scotland, produced flawed data over six years.   |
Food Processing
March 2013
Biderman & Young |
How Food and Beverage Manufacturers Can Avoid Class Action Litigation The recent suits against energy drink makers are lessons for all food and beverage processors. |
Information Today
March 14, 2013 |
LexisNexis Announces Major Release of Concordance Evolution Concordance Evolution is the next generation of the company's fully installed enterprise review software product for electronic discovery and litigation document management. The new release is completely web-enabled, allowing for efficient implementation and deployment. |
Information Today
March 11, 2013 |
LexisNexis and Rosen Announce Technology Collaboration The applications are designed to provide very advanced capabilities to litigation teams during the early case assessment, processing, and review stages of electronic discovery. |
Information Today
March 11, 2013 |
Thomson Reuters Launches Practitioner Insights This offers practitioner-focused pages on Westlaw Next that bring legal professionals the exclusive current awareness information and analysis that they need to stay up to speed and lead in their practice area. |
Chemistry World
March 4, 2013
Andy Extance |
UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries. |
Chemistry World
March 1, 2013
Andrew Turley |
Dow rapped for $1bn tax scheme A US federal court has rejected two 'tax shelter transactions' by Dow -- designed to create $1 billion in deductions -- and imposed penalties on the firm. |
On Wall Street
March 1, 2013
Alan J. Foxman |
Giving Proper Thanks for a Referral How to walk the fine line between expressing gratitude for a referral and divulging a new client and also a discussion of the legal status of crowdfunding sites. |
Chemistry World
February 19, 2013
Andrew Turley |
Merck resolves Vytorin case for $688m Merck & Co has agreed to pay $688 million to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin). |
Pharmaceutical Executive
February 1, 2013
Julin et al. |
Fortuity and the First Amendment Caronia decision shows the staying power of Sorrell v. IMS Health. Don't bank just yet on putting your marketing muscle behind the safe and effective off-label uses of your FDA-approved drugs. |
| <Older 3271-3280 Newer> Return to current articles. |
